Expression Analysis of Platinum Sensitive and Resistant Epithelial Ovarian Cancer Patient Samples Reveals New Candidates for Targeted Therapies by Veskimäe, K et al.
www.transonc.com
Trans la t iona l Onco logy Volume 11 Number 5 October 2018 pp. 1160–1170 1160Expression Analysis of Platinum
Sensitive and Resistant Epithelial
Ovarian Cancer Patient Samples
Reveals New Candidates for
Targeted Therapies1K Veskimäe*,2, M Scaravilli†,‡, 2, W Niininen†,‡,
H Karvonen†,‡, S Jaatinen†,‡, M Nykter†,‡,
T Visakorpi†,‡, §, J Mäenpää*,‡, D Ungureanu†,‡ and
S Staff*,†
*Department of Obstetrics and Gynecology, Tampere
University Hospital, Tampere, Finland; †BioMediTech
Institute, University of Tampere, Tampere, Finland.; ‡Faculty
of Medicine and Life Sciences, University of Tampere,
Tampere, Finland; §Fimlab Laboratories, Tampere University
Hospital, Tampere, FinlandAbstract
Ovarian cancer has the highest mortality rate of all gynecologic malignancies. Identification of new biomarkers is
highly needed due to its late diagnosis and high recurrence rate. The objective of this study was to identify
mechanisms of therapy resistance and potential biomarkers by analyzing mRNA and protein expression from
samples derived from patients with platinum-sensitive and -resistant ovarian cancer (total cohort n = 53). The data
revealed new candidates for targeted therapies, such as GREB1 and ROR2. We showed that the development of
platinum resistance correlated with upregulation of ROR2, whereas GREB1 was downregulated. Moreover, we
demonstrated that high levels of ROR2 in platinum-resistant samples were associated with upregulation of Wnt5a,
STAT3 and NF-kB levels, suggesting that a crosstalk between the non-canonical Wnt5a-ROR2 and STAT3/NF-kB
signaling pathways. Upregulation of ROR2, Wnt5a, STAT3 and NF-kB was further detected in a platinum-resistant
cell-line model. The results of the present study provided insight into molecular mechanisms associated with
platinum resistance that could be further investigated to improve treatment strategies in this clinically challenging
gynecological cancer.
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Epithelial ovarian cancer (EOC) accounts for the majority of
mortality from gynecological cancers, with diagnosis often at a late
stage. Currently, the golden standard of treatment is primary
debulking surgery (PDS) followed by platinum-based chemotherapy
[1]. Although most patients initially respond to chemotherapy, cancer
cells will eventually develop resistance leading to relapse [2]. Despite
intensive efforts to improve targeted therapy in EOC, the five-year
survival rate is still only 30% for advanced disease [3]. Therefore,
increased knowledge about mechanisms of platinum resistance in
EOC treatment is needed in search for cure.
Genetically complex and unstable high-grade serous ovarian cancer
subtype (HGSC), accounting for approximately 50–70% of EOC,
represents the most aggressive histological subtype [4]. A large-scale
integrated genomic data analysis for HGSC identified TP53
mutations in almost 96% of tumors. Recurrent somatic mutations
were found in nine other genes including NF1, BRCA1, BRCA2,,
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Table 1. Characteristics of the Study Patients in the Microarray Cohort (n = 12)
Characteristic Platinum Sensitive * n (%) Platinum Resistant * n (%
All 6 6
PDS † 5 2
NACT ‡ 1 4
PARP § low 0 6
PARP § high 6 0
Age
mean (SD) 65 62
median (range) 63 (46–78) 62 (55–79)
Grade 3 ¶ 6 (100%) 6 (100%)
Stage #
FIGO st I 0 0
FIGO st II 0 0
FIGO st III and IV 6 6
Histology
serous 6 (100%) 6 (100%)
PFS ** (months) 28 3.5
* Sensitivity defined as relapse or event-free intervalN 12 months after completion of platinum based 1s
line therapy.
† PDS - primary debulking surgery.
‡ NACT - neoadjuvant therapy.
§ PARP - PARP activity in fresh frozen tumor tissue was assessed by an enzymatic chemiluminescens
assay in a previous study [20]; the cut-off level for high PARP activity was set to 203 pg/ml corresponding to
median value.
¶ Grade – Grade 3 represents high grade tumors.
# FIGO - International Federation of Gynecology.
** PFS - progression free survival.
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promoter methylation events, indicating biological and molecular
heterogeneity that should be considered when developing novel
therapeutic strategies [5].
While only 10%–15% of ovarian cancer patients carry BRCA1 or
BRCA2 mutations in their germline, ∼50% of ovarian cancers exhibit
a defect in the homologous recombination (HR) repair of DNA [6].
PARP-1 enzyme became an attractive target for chemotherapeutics
for its crucial function in single-strand breaks (SSBs) DNA repair
mechanism through base excision repair (BER) pathway [7]. The
concept of synthetic lethality has been used in genetic studies to
determine functional interactions and compensation among genes for
decades and has also been exploited in the development of PARP
(Poly (ADP-ribose) polymerase) inhibitors [8]. The responsiveness to
platinum and PARP inhibitors associates with so called BRCAness
profile showing independent prognostic value [9,10].
The chemotherapy resistance can arise due to multiple mecha-
nisms, such as drug target alteration, re-activation or amplification of
the oncogenic pathway, activation of parallel pathways, increased
DNA damage tolerance/repair, and deregulation of growth factor
receptors among others [11]. Deregulation of apoptosis and altered
phosphorylation (intracellular signaling), as well as metabolic
pathways represent the two main biological processes responsible
for oncogene-mediated drug resistance in ovarian cancer [12]. In this
context, activation of PI3K/AKT cell survival pathway plays a pivotal
role with NF-kB and STAT3 as the main mediations of these
intracellular events. On the other hand, tumor suppressor genes such
as BRCA1, BRCA2, MLH1 and p21 contribute to ovarian cancer
drug resistance via alterations in the DNA damage and repair
mechanisms, whereas RASSF1, TP53 and TP73 impair the apoptotic
machinery for the same outcome [13]. Epithelial-to-mesenchymal
transition (EMT) has also been implicated in HGSC invasiveness and
chemoresistance, and in vitro studies using ovarian cancer cell lines
have shown that more aggressive, mesenchymal-type cells are more
resistant to cisplatin treatment [14]. An important signaling cascade
involved in EMT is the Wnt signaling, with increasing evidence
suggesting that β-catenin-independent pathway via Wnt5a/ROR1/
ROR2 has a critical role in EMT and chemoresistance [15–18].
Consequently, therapies targeting these pathways may offer means to
overcome drug resistance.
Active and also productive research in the field of cancer therapy has led
to an improved understanding of the molecular mechanisms, providing
insight into the development of cancer. This new data has led to the
development of new treatment options for cancer patients, including
targeted therapies and associated biomarker tests that can select which
patients are most likely to respond [19]. The aim of this study was to
identify candidate genes and their molecular pathways involved in the
pathogenesis of ovarian cancer associating with platinum resistance.
Overcoming the paucity of obtaining large collection of tumor samples
available for molecular profiling, we investigated differences in mRNA
and protein expression between ovarian cancer samples derived from two
clinically and molecularly distinct patient cohorts namely high PARP/
platinum-sensitive and low PARP/platinum-resistant HGSC cohorts.
This comparison aimed at distinction of two cohorts with extremely
different clinical behavior. Finally, this analysis led to identification of
GREB1 and ROR2 that showed significant differential expression profile
between the two groups. Our data suggest new predictive biomarkers for
ovarian cancer drug resistance development warranting further
investigations.Materials and Methods
Study Cohort and Tissue Samples
The study was carried out at the University of Tampere and
Tampere University Hospital (TAUH), Tampere, Finland. The study
protocol was approved by the Ethics Committee of TAUH
(identification code ETL-R11137).
The microarray study cohort consisted of 12 HGSC patients who
participated in a prospective study addressing PARP enzyme activity
in fresh ovarian cancer tumor samples [20]. The selection of this
patient subcohort was based on PARP values (high PARP/low PARP,
cut off 203 pg/ml, which corresponded to the median value of PARP)
and platinum sensitivity/resistance (treatment response), with no
differences in respect of age and FIGO (International Federation of
Gynecology). Platinum sensitivity was defined as no recurrence
within 12 months after the completion of first-line platinum-based
chemotherapy. Patient characteristics are presented in Table 1.
The validation cohort of the microarray data consisted of all the
patients (n = 53) that participated in the previous prospective study
[20]. The median follow-up time of patients was 31 months. The
validation cohort is described in Table 2.
For further investigation of ROR2 in EOC, a retrospective
subcohort was chosen from the study cohorts described above
consisting of a subgroup of patients who had not received NACT
(neoadjuvant chemotherapy) and were divided in two categories
based on treatment response, i.e. either platinum-sensitive or
platinum-resistant (Table 3).
The tumor tissue samples were collected at surgery, two samples
approximately 0.5 cm were chosen at the operation room from
macroscopically visible tumor and were snap-frozen with liquid
nitrogen and stored in −70 °C. The findings from the corresponding
archival surgical tumor specimens were assessed by experienced
pathologists as part of routine diagnostics at the Department of
Pathology at TAUH.)
t
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Table 2. Characteristics of the Study Patients in the Validation Cohort (n = 53)
Characteristic
Patients in study, n 53
Age at surgery, yrs. (SD) 66 (9.3)
BMI, mean (SD) 26.8 (6.2)
Median follow-up, months (range) 31 (2–50)
Ca 125 level (kU/L) before treatment, median (range) 523 (30–4728)
FIGO * Stage, n (%)
Stage 1 2 (3,7%)
Stage 2 3 (5,6%)
Stage 3 34 (64,3%)
Stage 4 14 (26,4%)
Histology, n (%)
Serous 46 (86,8)
Endometroid 4 (7,6%)
Papillar 2 (3,7%)
Mucinous 0 (0%)
Carcinosarcoma 0 (0%)
Transitional cell 1 (1,9%)
Grade †, n (%)
Grade 1 and 2 10 (18%)
Grade 3 43 (82%)
Sensitivity to platinum therapy ‡, n (%)
Sensitive 25 (47,2%)
Resistant 15 (28,3%)
Partial sensitive 13 (24,5%)
Neoadjuvant therapy, n (%) 19 (36%)
Recurrence 36 (68%)
Death 22 (42%)
* FIGO = International Federation of Gynecology.
† Grade – Grade 3 represents high grade tumors, Grade 1 and 2 low grade tumors.
‡ Sensitive: Recurrence N12 months after completion of platinum-based 1st line therapy; Resistant:
Recurrence ≤6 months after completion of platinum-based 1st line therapy; Partially sensitive: Recurrence 6–
12 months after completion of platinum-based 1st line therapy.
GREB1 fw 5’ATGGGAAATTCTTACGCTGGAC
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Total RNA from ovarian cancer fresh frozen samples was extracted
using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), according to the
manufacturer's protocol. The quality and integrity of the RNA was
assessed using Fragment Analyzer parallel capillary electrophoresisable 3. Characteristics of the study patients in the ROR investigation subcohort (n = 30)
haracteristic
atients in study, n 30
ge at surgery, yrs mean (SD) 66 (9.3)
edian follow-up, months (range) 31 (2–50)
IGO * Stage, n (%)
Stage 1 2 (6,7%)
Stage 2 4 (14%)
Stage 3 17 (56%)
Stage 4 7(23,3%)
istology, n (%)
Serous 22(73,3%)
Endometroid 2 (6,7%)
apillar 2 (6,7%)
Mucinous 2 (6,7%)
Carcinosarcoma 1 (3,3%)
ransitional cell 1 (3,3%)
rade †, n (%)
Grade 1 and 2 8 (26,7%)
Grade 3 22 (73,3%)
esponse to platinum therapy ‡, n (%)
Sensitive 20 (66,7%)
Resistant 10 (33,3%)
ecurrence 20 (66,7%)
eath 9 (30%)
* FIGO = International Federation of Gynecology.
† Grade – Grade 3 represents high grade tumors, Grade 1 and 2 low grade tumors.
‡ Sensitivity defined as relapse or event-free follow up timeN 12 months after completion of platinum
ased 1st line therapy.
GREB1 rev 5’CACTCGGCTACCACCTTCT
ROR2 fw 5’GTGCGGTGGCTAAAGAATGAT
ROR2 rev 5’ATTCGCAGTCGTGAACCATATT
TBP fw 5’GAATATAATCCCAAGCGGTTTG
TBP rev 5’ACTTCACATCACAGCTCCCCT
C
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A
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D
b(Advanced Analytical Technologies, Ankeny, IA, USA). The RNA was
subsequently labeled and hybridized using the Agilent gene expression
microarray kit (Agilent Technologies, Santa Clara, CA, USA), according
to the manufacturer's instruction. Briefly, the RNA from the clinical
samples was labeled with Cy3 fluorochrome and subsequently
co-hybridized with Cy5 labeled Xpress Ref TM Human Universal
Reference Total RNA (SuperArray Bio-science Corporation) as a control.
The hybridizationwas carried out for 21 hours onAgilent 4X44Khuman
gene expression array slides. The slides were subsequently scanned on an
Agilent C scanner and raw data were extracted using the Agilent Feature
Extraction software ver. 11.0.1.1 and quantile normalized. A fold-change
cutoff of 2 was used to determine differential mRNA expression as well as
q-value and signal intensity.
qRT-PCR
Putatively differentially expressed genes (ROR2, CAST, ATP6V1D,
GUCY1A3, TMOD1, MYCN, DLK1, PLEKHG4B, GREB1,
B4GALNT4, SLC35F3, PTCH2, TNNC1, BNC1) were selected
from the array results based on fold change, q-value, signal intensity
and literature data and were validated by quantitative real-time
polymerase chain reaction (qRT-PCR). Total RNA from ovarian
cancer fresh frozen tumor samples were extracted with TRIzol as
described above and were reverse transcribed using random hexamere
primers and MultiScribe reverse transcriptase (Thermo Fischer
Scientific, Waltham, MA, USA). Quantitative Real Time PCR was
performed using Maxima SYBR Green/ROX qPCR Master Mix
(Thermo Fischer Scientific) on a BioRad CFX96 ™ Real-Time PCR
Detection System (BioRad Laboratories, Hercules, CA, USA). Each
sample was run in duplicate and expression values were normalized
against the TATA-binding protein (TBP). The primer sequences for
the two validated genes are as follows:Western blotting
Frozen tumor pieces were thawed, washed 2X with cold PBS and
pestered to lyse in lysis buffer (50 mMTris–HCl pH 7.5, 10% glycerol,
150 mM NaCl, 1 mM EDTA, 1% Triton-x-100, 50 mM NaF)
supplementedwith protease and phosphatase inhibitor cocktails (Bimake,
Houston, TX, USA). Lysates were mixed with 4X Laemmli loading
buffer and subjected to SDS-PAGE gel electrophoresis and Western
blotting. The primary antibodies used were as following: pAkt S473
(#4060), pMEK1/2 S217/221 (#9121), NF-κB p65 (#6956), pPI3K
p85 Y458/p55 Y199 (#4228), PI3K p85α (#13666), Rac-1 (#4651),
pSTAT3 Y705 (#9145), STAT3 (#9139), Wnt5a/b (#2530) (Cell
Signaling Technology, Danvers, MA, USA); Akt (#sc-5298), Bcl-2
(#sc-7382), MEK1/2 (#sc-6250), β-tubulin (#sc-166,729) (Santa Cruz,
Dallas, TX, USA); ROR1 6D4 (Dr. Riddel lab, ref. Balakrishana et al.
2016); ROR2 (#565550, BD Biosciences, San Jose, CA, USA).
Secondary antibodies: IRDye® 800CW Donkey anti-Mouse IgG, or
IRDye® 680RDDonkey anti-Rabbit IgG (LI-COR, Lincoln, NE, USA).
Blots were scanned and quantified using Odyssey CLx and Image Studio
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expression level for each sample.
Cell Culture
A2780 and A2780cis cells were purchased from Merck & Company
Inc. (Kenilworth, NJ, USA) and cultured according to manufacturer's
recommendations. The A2780 line was maintained in medium
containing 1 μM cisplatin (Selleckchem, Munich, Germany). The
cisplatin EC50 response of A2780 and A2780cis cells was validated by
incubating cells with increasing concentration of cisplatin for 3 days and
cell viability was determined using CellTiterGlo (CTG) Assay (Promega,
USA) according to manufacturer's instructions.
qRT-PCR of the Ovarian Cancer Cell Lines
RNA was collected from A2780 and A2780cis using TRI Reagent®
(Molecular Research Center Inc. Cincinnati, OH, USA) according toTable 4. The 50 Most Upregulated mRNAs in High PARP and Platinum Sensitive OC Patient Sam
Gene name Gene description
COLEC11 collectin subfamily member 11
MYCN MYCN proto-oncogene. bHLH transcription factor
ESM1 endothelial cell specific molecule 1
IGF1R insulin like growth factor 1 receptor
TNNC1 troponin C1. slow skeletal and cardiac type
LGSN lengsin. Lens protein with glutamine synthetase domain
LOC100134423 uncharacterized LOC100134423
DLK1 delta like non-canonical Notch ligand 1
CRYGC crystallin gamma C
A_33_P3286709 NA
PLEKHG4B pleckstrin homology and RhoGEF domain containing G4B
TSPAN8 tetraspanin 8
ENPP6 ectonucleotide pyrophosphatase/phosphodiesterase 6
FLJ30901 uncharacterized protein FLJ30901
PROM1 prominin 1
COL22A1 collagen type XXII alpha 1 chain
KIAA1324 KIAA1324
PTCH2 patched 2
SLC35F3 solute carrier family 35 member F3
GABRG3 gamma-aminobutyric acid type A receptor gamma3 subunit
LOC613266 uncharacterized LOC613266
LCE1E late cornified envelope 1E
B4GALNT4 beta-1.4-N-acetyl-galactosaminyltransferase 4
STC2 stanniocalcin 2
FOXL2NB FOXL2 neighbor
AK124496 NA
CU677518 NA
NM_130777 NA
NR_102701 NA
NSG1 neuronal vesicle trafficking associated 1
STAR steroidogenic acute regulatory protein
MCTS2P malignant T-cell amplified sequence 2. pseudogene
TRABD2A TraB domain containing 2A
DEPTOR DEP domain containing MTOR interacting protein
CLEC4GP1 C-type lectin domain family 4 member G pseudogene 1
LINC01405 long intergenic non-protein coding RNA 1405
COL2A1 collagen type II alpha 1 chain
HS6ST2 heparan sulfate 6-O-sulfotransferase 2
PRAME preferentially expressed antigen in melanoma
LINC02398 long intergenic non-protein coding RNA 2398
GJB7 gap junction protein beta 7
PLCXD3 phosphatidylinositol specific phospholipase C X domain containi
ERVI-1 endogenous retrovirus group I member 1
ZNF556 zinc finger protein 556
NTS neurotensin
BU963192 NA
GMNC geminin coiled-coil domain containing
A_33_P3274001 NA
CRYGD crystallin gamma D
GREB1 growth regulation by estrogen in breast cancer 1
mRNAs selected for further validation are shown in bold.the manufacturer's protocol. qRT-PCR was performed as described
for the ovarian cancer clinical samples. Each cell line was run in 4
replicates and the expression of ROR2 and GREB1 was normalized
against TBP.
Statistical Analysis
The statistical analysis of mRNA microarray data was implemented
in R using packages limma and preprocessCore of Bioconductor
project [21–23]. Data was quantile normalized and probe sets were
summarized by choosing the probes with the highest average
expression [22]. Using limma approach, differential expression was
identified between patients who had low PARP value and were
platinum resistant, and patients who had high PARP value and were
platinum sensitive [23]. P-values were obtained by the empirical
Bayes moderated t-test. A fold-change cutoff of 2 was used to
determine differential mRNA expression. The results wereples in Comparison to low PARP and Platinum Resistant Samples.
log2-fold change p-value q-value
3.68E+ 00 1.29E-02 0.2588936
3.61E+ 00 2.74E-04 0.1050305
3.18E+ 00 1.64E-04 0.1028588
3.08E+ 00 5.29E-03 0.211962
3.04E+ 00 1.25E-05 0.0472319
3.02E+ 00 1.25E-02 0.2588936
2.97E+ 00 2.71E-04 0.1050305
2.89E+ 00 4.17E-03 0.2013983
2.86E+ 00 2.37E-03 0.1822358
2.82E+ 00 9.15E-05 0.0864965
2.82E+ 00 1.17E-03 0.1525447
2.78E+ 00 2.99E-02 0.3064189
2.73E+ 00 1.20E-02 0.2563874
2.60E+ 00 3.26E-04 0.1050305
2.59E+ 00 3.02E-02 0.3079072
2.58E+ 00 2.64E-03 0.1844765
2.58E+ 00 5.48E-04 0.1261184
2.57E+ 00 1.93E-05 0.0472319
2.54E+ 00 3.87E-05 0.0596903
2.51E+ 00 4.50E-05 0.0628517
2.50E+ 00 4.89E-02 0.3485897
2.49E+ 00 2.28E-04 0.1050305
2.49E+ 00 1.24E-05 0.0472319
2.48E+ 00 2.86E-04 0.1050305
2.48E+ 00 1.04E-01 0.4447586
2.47E+ 00 2.78E-02 0.3020977
2.47E+ 00 2.82E-06 0.0275612
2.45E+ 00 1.10E-02 0.2525629
2.43E+ 00 2.11E-03 0.1762016
2.43E+ 00 1.05E-03 0.1525447
2.41E+ 00 5.08E-03 0.2110634
2.40E+ 00 5.43E-03 0.2134259
2.36E+ 00 4.89E-03 0.2078187
2.35E+ 00 4.70E-04 0.125416
2.35E+ 00 4.56E-03 0.2021535
2.33E+ 00 6.95E-04 0.1391319
2.32E+ 00 1.82E-02 0.2816697
2.31E+ 00 2.15E-02 0.2871745
2.30E+ 00 4.32E-05 0.0628517
2.29E+ 00 1.08E-05 0.0472319
2.29E+ 00 3.18E-02 0.3122712
ng 3 2.28E+ 00 6.03E-02 0.3707384
2.27E+ 00 1.28E-02 0.2588936
2.27E+ 00 1.46E-06 0.0213888
2.26E+ 00 6.56E-02 0.3828556
2.25E+ 00 7.17E-05 0.0751488
2.24E+ 00 1.52E-02 0.2689731
2.24E+ 00 9.36E-05 0.0864965
2.24E+ 00 2.58E-02 0.2964626
2.22E+ 00 1.22E-03 0.1542519
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clustering.
qRT-PCR data were analyzed using the Student's t-test and
Mann–Whitney U test where appropriate. The Kaplan–Meier
regression analyses were used to estimate the survival rates from the
date of surgery (primary debulked patients) or from the date of the
first dose of neoadjuvant therapy until the date of the event of
interest. For progression-free survival (PFS), the event of interest was
a recurrence or death, whichever occurred first. Patients alive at the
last follow-up without a recurrence were censored at the last follow-up
date. Statistical analysis was performed using GraphPad Prism 6
software for Windows (GraphPad Software Inc., La Jolla, CA, USA).
A p-value less than 0.05 was considered significant.
Oncomine (https://www.oncomine.org/resource/login.html) and
Kaplan–Meier plotter (http://kmplot.com/analysis/index.php?p=Table 5. The 50 Most Downregulated mRNAs in High PARP and Platinum Sensitive OC Patient S
Gene Name Gene Description
EFEMP1 EGF containing fibulin extracellular matrix protein 1
FAP fibroblast activation protein alpha
TMOD1 tropomodulin 1
BNC1 basonuclin 1
ENST00000453673 NA
ENST00000411475 NA
SCRG1 stimulator of chondrogenesis 1
PTGFR prostaglandin F receptor
POSTN periostin
ENST00000390237 NA
BF175071 NA
GUCY1A3 guanylate cyclase 1 soluble subunit alpha
ENST00000390628 NA
CXCL13 C-X-C motif chemokine ligand 13
ACKR4 atypical chemokine receptor 4
IGLL5 immunoglobulin lambda like polypeptide 5
AREG amphiregulin
A_33_P3251412 NA
FYB1 FYN binding protein 1
CD38 CD38 molecule
ENST00000468879 NA
ENST00000390252 NA
JCHAIN joining chain of multimeric IgA and IgM
ENST00000390547 NA
MEDAG mesenteric estrogen dependent adipogenesis
CNR1 cannabinoid receptor 1
PRRX1 paired related homeobox 1
NR4A3 nuclear receptor subfamily 4 group A member 3
CH25H cholesterol 25-hydroxylase
AB363267 NA
ENST00000426099 NA
CCL18 C-C motif chemokine ligand 18
THBS2 thrombospondin 2
ENST00000410078 NA
BCHE butyrylcholinesterase
ATP6V1D ATPase H+ transporting V1 subunit D
ENST00000390323 NA
CCR2 C-C motif chemokine receptor 2
ENST00000479981 NA
CAST calpastatin
ASPN asporin
HBB hemoglobin subunit beta
ENST00000390247 NA
SULF1 sulfatase 1
EPYC epiphycan
FGFBP1 fibroblast growth factor binding protein 1
LRRC15 leucine rich repeat containing 15
DOCK11 dedicator of cytokinesis 11
OOEP oocyte expressed protein
ROR2 receptor tyrosine kinase like orphan receptor 2
mRNAs selected for further validation are shown in bold.service&cancer=ovar) databases were searched for gene expression
and survival data.
Results
Microarray Analysis of HGSC Patient Samples
In order to identify differentially expressed genes between ovarian
cancer samples with platinum-sensitivity with high PARP levels and
samples with platinum resistance with low PARP levels (n = 12),
gene expression microarray was performed on total RNA isolated
from the freshly frozen tumor samples. The analysis of gene
expression showed a total of 3001 differentially expressed genes
between the two comparison groups when a log fold change cutoff 2
was implemented. In this comparison, 1463 genes were downregu-
lated and 1538 genes were upregulated. 50 most upregulated and 50amples in Comparison to Low PARP and Platinum Resistant Samples
Log2-Fold Change p-Value q-Value
−3.85E+ 00 1.50E-03 0.1587368
−3.66E+ 00 9.07E-04 0.1525447
−3.41E+ 00 2.92E-08 0.0008577
−3.36E+ 00 2.74E-04 0.1050305
−3.22E+ 00 2.22E-02 0.2877726
−3.18E+ 00 2.30E-02 0.2898232
−3.18E+ 00 1.64E-03 0.1627023
−3.04E+ 00 1.05E-03 0.1525447
−3.01E+ 00 1.10E-02 0.2525629
−2.97E+ 00 1.54E-02 0.2695379
−2.92E+ 00 5.12E-02 0.3538495
−2.89E+ 00 5.68E-05 0.0723946
−2.87E+ 00 4.44E-03 0.2021325
−2.87E+ 00 1.02E-02 0.2487313
−2.86E+ 00 9.73E-05 0.0864965
−2.86E+ 00 3.46E-02 0.318167
−2.83E+ 00 1.43E-02 0.2670241
−2.81E+ 00 1.46E-02 0.2682963
−2.79E+ 00 2.51E-03 0.1843078
−2.78E+ 00 1.54E-03 0.1587368
−2.77E+ 00 4.36E-02 0.3380632
−2.73E+ 00 1.49E-02 0.2682963
−2.70E+ 00 6.61E-03 0.2195342
−2.69E+ 00 5.85E-03 0.2163421
−2.69E+ 00 4.49E-02 0.3403785
−2.68E+ 00 9.85E-03 0.2471112
−2.68E+ 00 7.45E-04 0.1427284
−2.67E+ 00 2.00E-02 0.2850432
−2.65E+ 00 2.21E-03 0.1762175
−2.65E+ 00 4.23E-02 0.3347815
−2.63E+ 00 4.11E-02 0.331398
−2.57E+ 00 1.16E-04 0.0898927
−2.57E+ 00 3.91E-02 0.327707
−2.56E+ 00 5.30E-02 0.3580372
−2.55E+ 00 1.00E-02 0.2471753
−2.55E+ 00 1.54E-04 0.1028588
−2.55E+ 00 2.42E-02 0.2937808
−2.54E+ 00 9.37E-03 0.24523
−2.54E+ 00 9.43E-03 0.24523
−2.54E+ 00 1.02E-03 0.1525447
−2.52E+ 00 2.94E-02 0.3049408
−2.52E+ 00 2.08E-02 0.2862875
−2.51E+ 00 2.16E-02 0.2871745
−2.50E+ 00 1.80E-02 0.2805948
−2.49E+ 00 1.28E-02 0.2588936
−2.49E+ 00 1.03E-02 0.2499163
−2.48E+ 00 4.14E-02 0.3321649
−2.45E+ 00 5.13E-04 0.1261184
−2.45E+ 00 4.23E-03 0.2013983
−1.84E+ 00 2.83E-05 0.0506967
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respectively. The comparison of patient groups according to PARP
levels and treatment responses are shown in Figure 1, a-b.
GREB1 and ROR2 are Significantly Differentially Expressed
inOvarianCancer Tumor Samples Based on PlatinumSensitivity
and PARP Levels
Fourteen differentially expressed mRNAs (namely: ROR2, CAST,
ATP6V1D, GUCY1A3, TMOD1, MYCN, DLK1, PLEKHG4B,
GREB1, B4GALNT4, SLC35F3, PTCH2, TNNC1, BNC1) from the
microarray analysis were selected for validation by qRT-PCR in the
cohort of 53 ovarian cancer patients, based on fold change, q-value,
signal intensity and previous literature (Table 2). Two genes, namely
ROR2 and GREB1, were significantly differentially expressed in high
PARP/platinum-sensitive vs. low PARP/platinum-resistant groups
(P = .02 and 0.002, respectively) (Figure 2, a-b). ROR2 was
downregulated in microarray data in high PARP/platinum-sensitive
tumor samples and the same result was obtained by qRT-PCR
analysis in the validation cohort (n = 53). A trend towards statistically
significant difference between the platinum sensitive and resistant
groups regardless of PARP levels was observed (P = .058) (Figure 2a).
The comparisons described above were based on treatment response
as a significant clinical feature and issue of interest. In addition,
previously determined PARP levels were taken into account to further
investigate tumors from the BRCAness profile point of view. The
platinum sensitive and high PARP level cohort is considered a group
of better prognosis befitting with the BRCAness profile, whereas the
platinum resistant and low PARP level a group with poorer prognosis.
On the other hand, GREB1 was upregulated in microarray data in
high PARP/platinum-sensitive tumor samples, and this result wasFigure 1. a. Scatterplot showing location of samples of high PARP and
along the first two principal components (PC1 and PC2). Platinum sens
PARP and platinum resistant samples by purple dots.b. Unsupervise
patterns in patients with high PARP levels and platinum sensitivity covalidated by qRT-PCR (Figure 2b). Furthermore, GREB1 also
showed a trend of overexpression in platinum sensitive samples,
regardless of PARP level (P = .26).
GREB1 Expression Defines Platinum Sensitivity and Correlates
with Longer PFS in Ovarian Cancer
Furthermore, we investigated whether GREB1 expression affects
PFS in ovarian cancer patients (n = 53). High GREB1 expression was
significantly associated with longer PFS as shown in Figure 2c (P =
.019 in log-rank test). In Kaplan–Meier database search, which
included 1465 ovarian cancer patients, a similar result was shown
associating high GREB1 expression with better PFS (P = 0,014 in
log-rank test), as shown in Figure 2d. In addition to Kaplan–Meier
plotter database and Oncomine (website links are reported in
statistical analysis section) were searched for the ROR2 and GREB1
genes. No similar results in expression correlation were found,
however, no similar study settings were found (HGSC, treatment
response comparison).
High ROR2 Expression in LowPARP/Platinum Resistant
Ovarian Cancer Samples Correlated with HigherWnt5a, STAT3
and NF-kB levels
Previous data have shown no association with ROR2 expression
and relapse-free survival [25] in ovarian cancer. However, ROR2 and
ROR1 expression is increased in cisplatin resistant A2780 cell line
compared to parental cells ([18]), and silencing their ligand Wnt5a in
serous adenocarcinoma OVCAR3 cell line had greater effect in
inhibiting cell migration and invasion than silencing either ROR
alone [25]. Since ROR2 was significantly upregulated in low PARP/
platinum-resistant patient samples in our microarray data, we decidedplatinum sensitive and low PARP and platinum resistant in patients
itive and high PARP level samples are represented by black and low
d clustering of the clinical samples shows differential expression
mpared to patients with low PARP levels and platinum resistant.
Figure 2. a. Expression of ROR2 and GREB1 in platinum sensitive (n = 38) vs resistant (n = 15) samples as well as high PARP level and
platinum sensitive (n = 17) vs low PARP level and platinum resistant (n = 14) samples according to qRT-PCR (P = .02 and 0.002
respectively). The graphs show mean ± SEM.b. Kaplan–Meier analysis of progression free survival (PFS) according to median level of
GREB 1 concentration (log rank P = .019). Vertical lines represent censored patients.c. Kaplan–Meier analysis of progression free survival
(PFS) according to median level of GREB 1 concentration (log-rank P = .014) from Kaplan–Meier plotter database.
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proteins by Western blot in a subcohort of samples described in
Table 3. As shown in Figure 3a-b, higher expression levels of Wnt5a,
ROR1 and ROR2 proteins were found in low PARP/
p l a t inum-re s i s t ant g roup compared to h igh PARP/
platinum-sensitive group. Moreover, upregulation of downstream
signaling mediators such as pSTAT3 (Y705) and NF-kB was also
observed in tumor lysates from low PARP/platinum resistant group.
Noteworthy, patient samples with high levels of ROR1 and ROR2
from low PARP/platinum-resistant group showed higher pSTAT3
(Y705) levels (Figure 3a), indicating that STAT3 could mediate
signaling downstream ROR1 and ROR2. Database search (Oncomine,Kaplan–Meier plotter; website links are reported in statistical analysis
section) revealed no additional information regarding ROR in therapy
response and ovarian cancer setting.
ROR2 and GREB1 Show Differential Expression in Cisplatin
Resistant Ovarian Cancer Cell Line Model
The human epithelial ovarian cancer cell line A2780 and its
cisplatin resistant model A2780cis were selected to investigate the
expression levels of ROR2 and GREB1. We confirmed the
chemoresistant phenotype of A2780cis cells compared to A2780
parental cells by CTG assay and found significant increase of EC50 to
cisplatin treatment for A2780cis cells (Figure 4a). The expression of
NF-kB p65
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Figure 3. Wnt5a/ROR2 expression is increased in lysates from platinum resistant tumors. A. Western blot analysis of lysates from
platinum resistant vs. platinum sensitive patient samples with the indicated primary antibodies. B. Quantification of protein expression for
Wnt5a, ROR2, STAT3 and NF-kB based on β-tubulin levels. Horizontal lines represent the average and errors bars are SEM (standard error
of mean). After normalization, samples were quantified based on the highest expression level of all samples.
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A2780cis cells (Figure 4b and c). We observed ROR2 mRNA
upregulation in platinum resistant cell line A2780cis compared to
platinum sensitive A2780 cells (P = .0046), as previously shown
([18]), whereas GREB1 mRNA level was downregulated in A2780cis
compared to A2780 parental cells (P = .0012). Furthermore,
A2780cis cells have increased protein expression levels of ROR2
and Wnt5a compared with the parental A2780 cells as shown by
Western blotting of cytoplasmic cell lysates (Figure 4d). In addition,
we detected higher nuclear expression levels for STAT3 and NF-kB
in chemoresistant A2780cis compared to parental A2780 cells
(Figure 4d). Thus, our microarray data from patient samples are
validated in chemoresistant ovarian cancer cell line and investigations
are ongoing to decipher the molecular mechanisms employed byROR2 and GREB1 for their differential expression associated with
cisplatin resistance.
Discussion
Due to its poor prognosis, identification of new therapeutic
approaches is highly needed in ovarian cancer. Although approxi-
mately 50% of HGSC tumors with HR defects may benefit from
PARP inhibitors, beyond this, identification of other commonly
deregulated pathways could provide opportunities for better
therapeutic interventions. As such, our goal was to examine gene
and protein expression in a HGSC tumor sample cohort defined by
response to platinum therapy and the level of PARP expression.
Patients were carefully stratified based on their PARP levels and
platinum responsiveness as previously indicated [20] and monitored
Figure 4. a. Cisplatin sensitivity testing of A2780 and A2780cis cell lines. Cells were incubated as five replicates for 3 days with increased
concentrations of cisplatin as indicated and cell-viability was measured by CTG assay. EC50 was calculated using Graph Prism software
and shown as approximate values.b. ROR2 mRNA expression in platinum sensitive and resistant cell lines A2780/A2780cis (P = .0046).
The graphs show mean ± SEM.c. GREB1 mRNA expression in platinum sensitive and resistant cell lines A2780/A2780cis (P = .0012.
The graphs show mean ± SEM.d. Protein expression levels for ROR2, Wnt5a, NF-kB and STAT3 in the cytoplasmic and nuclear cell
lysates of A2780 and A2780cis cell lines. Protein quantification was done using Oddyssey Licor software and normalized against the
loading control.
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analysis of their disease progression.
Two functionally unrelated genes, GREB1 and ROR2 were
identified in our analysis as significantly differentially expressed
between high PARP/platinum-sensitive and low PARP/
platinum-resistant groups.While initially sequenced from brain tissue, human GREB1 is
highly expressed in normal and neoplastic ovarian tissue and in several
other hormone-responsive tissues such as breast, uterine and prostate
[26–29]. GREB1, along with CCND1 and MYC, are common
transcription targets for E2 (17β-estradiol)-mediated proliferative
responses, via ESR1 (estrogen receptor one) engagement [28].
The authors declare no conflicts of interest.
org/10.1093/jjco/hyu007.
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GREB1, whereas in ovarian cancer, its expression could be detected in
both, ESR1+ or estrogen receptor negative (ESR1−) tumors.
ESR1-independent expression of GREB1 may indicate the existence
of other signaling pathways for estrogen-promoting growth in the
absence of E2 and/or ESR1, underlining differences in
E2-responsiveness between breast and ovarian cancer that play an
important role in response to antiestrogenic therapies [30]. GREB1
was upregulated in all EOC tumors and was suggested to have
potential biomarker role in ovarian cancer [29]. GREB1 was
upregulated in our microarray data in high PARP/
platinum-sensitive patients, and high GREB1 expression was
associated with longer PFS, suggesting a prognostic value for
GREB1 in ovarian cancer.
It has been demonstrated that GREB1 knockdown inhibits
proliferation of ovarian cancer cell lines and consequently, prolongs
survival in an orthotopic mouse model [28]. Also, hypomethylation at
specific CpG site associated with GREB1 has been associated with
longer PFS in ovarian cancer in a DNAmethylation study designed to
investigate epigenetic modifications [31]. Interestingly, loss of
GREB1 has been linked to tamoxifen resistance in breast cancer
due to loss of sensitivity to endocrine agents in general, underlining its
important role in endocrine resistance [32–33]. Although endocrine
therapy has overall limited efficacy in ovarian cancer patients, more
research is needed to assess whether GREB1 is associated with
antiestrogen sensitivity in this cancer. In view of this previous data,
our results are in accordance with these findings reaffirming the
understanding that GREB1 is highly expressed in high PARP/
platinum-sensitive patient group that has been associated with a
positive outcome befitting with the BRCAness profile [10]. Our data
show for the first time that GREB1 could have prognostic value in
ovarian cancer and warrants further investigation, especially associ-
ated with response to hormone-based therapy.
ROR2 belongs to the ROR receptor family (ROR1 and ROR2)
from the non-canonical Wnt pathway [17]. ROR1 and ROR2 form
heterodimers in response to Wnt5a, which leads to RhoA/Rac1
activation and increases migration and invasion properties of cancer
cells [34]. Recent studies have demonstrated that upregulation of
ROR2 and its ligand Wnt5a in EOC regulates EMT and correlates
with worse prognosis [35]. ROR1 and ROR2 regulate migration and
invasion of ovarian cancer cells and more importantly, their
expression was increased in platinum resistant A2780 ovarian cancer
cell line compared to parental cells ([18]). TCGA data analysis of over
500 ovarian tumor samples identified high expression of Wnt5a and
Wnt5a protein was found prevalent in ascites samples of ovarian
cancer patients [36]. In our study, ROR2 gene expression was
significantly upregulated in low PARP/platinum-resistant vs. high
PARP/platinum-sensitive patient samples. We also found higher
protein levels of ROR2, ROR1 and Wnt5a ligand in lysates of
platinum-resistant tumors (Figure 3, a-b), confirming our gene
expression analysis. Interestingly, higher expression levels of NF-κB
and pSTAT3 (Y705) proteins were also noted in platinum-resistant
tumor lysate with high ROR1 and ROR2 levels, indicating that
STAT3 could be downstream mediator of ROR signaling in ovarian
cancer. These results showing Wnt5a-ROR2 and STAT3/NF-kB
signaling pathway in clinical ovarian tumor samples are novel
findings. A direct link between ROR1 and STAT3 expression has
been demonstrated previously in leukemia, showing that STAT3
promoter harbors two ROR1 binding sites [37]. Moreover, previousstudies have shown that Wnt5a is involved in cancer multidrug
resistance (MDR)[36]. High Wnt5a expression levels in ovarian
cancer cell lines correlated with lower chemosensitivity to paclitaxel,
oxaliplatin, 5-fluorouracil, epirubicin and etoposide ([38,39].
Furthermore, upregulation of Wnt5a and ROR2 was detected in
colon cancer cells resistant to butyrate, a histone deacetylase inhibitor
(HDACi)[40], along with activation of AKT/PKB (protein kinase B)
signaling pathway. Wnt5a orchestrates multiple signaling networks
involved in chronic inflammation and carcinogenesis, and crosstalk
with STAT3 and NF-κB pathways have been previously documented
[41]. Thus, upregulation of Wnt5a, ROR1 and ROR2 signaling
pathways could be common mechanisms in ovarian cancer
chemoresistance and could serve as putative biomarkers. ROR1
targeted therapies have shown promising results in preclinical and
clinical models, with anti-ROR1 monoclonal antibody cirmtuzumab
being efficient not only in leukemia, but also in ovarian cancer [42],
indicative of high therapeutic potential for targeting these receptors.
Our mRNA expression data from patient samples were validated
using a cisplatin resistant cell line model A2780cis and we found that
upregulation of ROR2 at the mRNA and protein levels is associated
with cisplatin resistance. Moreover, GREB1 mRNA level was
downregulated in A2780cis compared to A2780 parental cells.
Furthermore, we observed higher expression levels for Wnt5a,
STAT3 and NF-kB proteins in chemoresistant A2780cis cells
compared to parental cells, in support of our results from patient
samples (Figure 3).
In conclusion, we found the expression of ROR2 and GREB1 to
be associated with treatment response in HGSC. The association
between Wnt5a/ROR2 expression and development of platinum
resistance reported herein suggests that the Wnt5a/ROR2 pathway is
potentially actionable for possible modulation of chemoresistance.
Because silencing ROR1 and ROR2 restores the chemosensitivity of
carboplatin-resistant ovarian cancer cells [18], a combination of ROR
antagonists and chemotherapeutic agents may offer a promising
treatment option. Also, our findings regarding GREB1 expression in
highPARP/platinum-sensitive patients should reinforce the interest in
this gene for future investigations.
Acknowledgements
We sincerely thank Mrs. Sari Toivola for her excellent assistance in
laboratory.
DisclosureReferences
[1] Nowak M, Głowacka E, Lewkowicz P, Banasik M, Szyłło K, Zimna K,
Bednarska K, and Klink M (2018). Sub-optimal primary surgery leads to
unfavorable immunological changes in ovarian cancer patients. Immunobiology
223, 1–7. https://doi.org/10.1016/j.imbio.2017.10.021.
[2] Heintz APM, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman
WT, Ngan HYS, Pecorelli S, and Beller U (2006). Carcinoma of the ovary.
FIGO 26th Annual Report on the Results of Treatment in Gynecological
Cancer. Int J Gynaecol Obstet 95(Suppl 1), S161–S192. https://doi.
org/10.1016/S0020-7292(06)60033-7.
[3] Matsuda A and Katanoda K (2014). Five-year Relative Survival Rate of Ovarian
Cancer in the USA, Europe and Japan. Jpn J Clin Oncol 44, 196. https://doi.
1170 Expression Analysis in Platinum Resistant Ovarian Cancer Veskimäe et al. Translational Oncology Vol. 11, No. xx, 2018[4] Levanon K, Crum C, and Drapkin R (2008). New insights into the pathogenesis
of serous ovarian cancer and its clinical impact. J Clin Oncol Off J Am Soc Clin
Oncol 26, 5284–5293. https://doi.org/10.1200/JCO.2008.18.1107.
[5] Cancer Genome Atlas Research Network (2011). Integrated genomic analyses of
o v a r i a n c a r c i n oma . Na t u r e 4 7 4 , 6 0 9 – 6 1 5 . h t t p s : / / d o i .
org/10.1038/nature10166.
[6] Bast RC (2011). Molecular approaches to personalizing management of ovarian
c anc e r . Ann Onco l 22 ( Supp l 8 ) , v i i i 5–v i i i 15 . h t tp s : / / do i .
org/10.1093/annonc/mdr516.
[7] Davar D, Beumer JH, Hamieh L, and Tawbi H (2012). Role of PARP inhibitors
in cancer biology and therapy. Curr Med Chem 19, 3907–3921.
[8] Fang B (2014). Development of synthetic lethality anticancer therapeutics. J Med
Chem 57, 7859–7873. https://doi.org/10.1021/jm500415t.
[9] Bast RC and Mills GB (2010). Personalizing therapy for ovarian cancer:
BRCAness and beyond. J Clin Oncol Off J Am Soc Clin Oncol 28, 3545–3548.
https://doi.org/10.1200/JCO.2010.28.5791.
[10] Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E,
Francoeur N, Levine DA, and Cannistra SA (2010). Gene expression profile of
BRCAness that correlates with responsiveness to chemotherapy and with
outcome in patients with epithelial ovarian cancer. J Clin Oncol Off J Am Soc Clin
Oncol 28, 3555–3561. https://doi.org/10.1200/JCO.2009.27.5719.
[11] Ramos P and Bentires-Alj M (2015). Mechanism-based cancer therapy:
resistance to therapy, therapy for resistance. Oncogene 34, 3617–3626. https:
//doi.org/10.1038/onc.2014.314.
[12] Liu X, Gao Y, Lu Y, Zhang J, Li L, and Yin F (2015). Oncogenes associated with
drug resistance in ovarian cancer. J Cancer Res Clin Oncol 141, 381–395. https:
//doi.org/10.1007/s00432-014-1765-5.
[13] Yin F, Liu X, Li D, Wang Q, Zhang W, and Li L (2013). Tumor suppressor
genes associated with drug resistance in ovarian cancer (Review). Oncol Rep 30,
3–10. https://doi.org/10.3892/or.2013.2446.
[14] Miow QH, Tan TZ, Ye J, Lau JA, Yokomizo T, Thiery J-P, and Mori S (2015).
Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian
cancer. Oncogene 34, 1899–1907. https://doi.org/10.1038/onc.2014.136.
[15] Baarsma HA, Königshoff M, and Gosens R (2013). TheWNT signaling pathway
from ligand secretion to gene transcription: molecular mechanisms and
pharmacological targets. Pharmacol Ther 138, 66–83. https://doi.
org/10.1016/j.pharmthera.2013.01.002.
[16] Ford CE, Henry C, Llamosas E, Djordjevic A, and Hacker N (2016). Wnt
signalling in gynaecological cancers: A future target for personalised medicine?
Gynecol Oncol 140, 345–351. https://doi.org/10.1016/j.ygyno.2015.09.085.
[17] Endo M, Nishita M, Fujii M, and Minami Y (2015). Insight into the role of
Wnt5a-induced signaling in normal and cancer cells. Int Rev Cell Mol Biol 314,
117–148. https://doi.org/10.1016/bs.ircmb.2014.10.003.
[18] Henry CE, Llamosas E, Djordjevic A, Hacker NF, and Ford CE (2016).
Migration and invasion is inhibited by silencing ROR1 and ROR2 in
chemoresistant ovarian cancer. Oncogene 5 , e226. https://doi.
org/10.1038/oncsis.2016.32.
[19] National Cancer Policy ForumBoard on Health Care ServicesHealth and
Medicine DivisionNational Academies of Sciences, Engineering, and Medicine
(2017.). The Drug Development Paradigm in Oncology: Proceedings of a
Workshop, The National Academies Collection: Reports funded by National
Institutes of Health. Washington (DC): National Academies Press (US); 2017.
[20] Veskimäe K, Staff S, Grönholm A, Pesu M, LaaksonenM, Nykter M, Isola J, and
Mäenpää J (2016). Assessment of PARP protein expression in epithelial ovarian
cancer by ELISA pharmacodynamic assay and immunohistochemistry. Tumour
Biol 37, 11991–11999. https://doi.org/10.1007/s13277-016-5062-6.
[21] Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B,
Gautier L, Ge Y, and Gentry J, et al (2004). Bioconductor: open software
development for computational biology and bioinformatics. Genome Biol 5, R80.
https://doi.org/10.1186/gb-2004-5-10-r80.
[22] Bolstad BM, Irizarry RA, Astrand M, and Speed TP (2003). A comparison of
normalization methods for high density oligonucleotide array data based on
variance and bias. Bioinformatics 19, 185–193.
[23] Smyth GK (2004). Linear models and empirical bayes methods for assessing
differential expression in microarray experiments. Stat Appl Genet Mol Biol 33.
https://doi.org/10.2202/1544-6115.1027.
[24] Mardia KV, Li Q, and Hainsworth TJ (1992). On the Penrose hypothesis on
fingerprint patterns. IMA J Math Appl Med Biol 9, 289–294.
[25] Henry C, Llamosas E, Knipprath-Meszaros A, Schoetzau A, Obermann E,
Fuenfschilling M, Caduff R, Fink D, Hacker N, and Ward R, et al (2015).Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits
cell migration and invasion. Oncotarget 6, 40310–40326. https://doi.
org/10.18632/oncotarget.5643.
[26] Hnatyszyn HJ, Liu M, Hilger A, Herbert L, Gomez-Fernandez CR, Jorda M,
Thomas D, Rae JM, El-Ashry D, and Lippman ME (2010). Correlation of
GREB1 mRNA with protein expression in breast cancer: validation of a novel
GREB1 monoclonal antibody. Breast Cancer Res Treat 122, 371–380. https:
//doi.org/10.1007/s10549-009-0584-x.
[27] Fung JN, Holdsworth-Carson SJ, Sapkota Y, Zhao ZZ, Jones L, Girling JE,
Paiva P, Healey M, Nyholt DR, and Rogers PAW, et al (2015). Functional
evaluation of genetic variants associated with endometriosis near GREB1. Hum
Reprod 30, 1263–1275. https://doi.org/10.1093/humrep/dev051.
[28] Pellegrini C, Gori I, Achtari C, Hornung D, Chardonnens E, Wunder D, Fiche
M, and Canny GO (2012). The expression of estrogen receptors as well as
GREB1, c-MYC, and cyclin D1, estrogen-regulated genes implicated in
proliferation, is increased in peritoneal endometriosis. Fertil Steril 98,
1200–1208. https://doi.org/10.1016/j.fertnstert.2012.06.056.
[29] Hodgkinson KM (2016). The role of steroid hormones, GREB1, and
reproductive status in ovarian cancer progression. Ottawa, Ontario, Canada:
Department of Cellular and Molecular Medicine University of Ottawa; 2016 .
[30] Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, Wang
YC, Duran GE, Sikic TL, and Caldeira S, et al (2003). Gene expression patterns
in ovarian carcinomas. Mol Biol Cell 14, 4376–4386. https://doi.
org/10.1091/mbc.E03-05-0279.
[31] Bauerschlag DO, Ammerpohl O, Bräutigam K, Schem C, Lin Q, Weigel MT,
Hilpert F, Arnold N, Maass N, and Meinhold-Heerlein I, et al (2011).
Progression-free survival in ovarian cancer is reflected in epigenetic DNA
methylation profiles. Oncology 80, 12–20. https://doi.org/10.1159/000327746.
[32] Mohammed H, D'Santos C, Serandour AA, Ali HR, Brown GD, Atkins A,
Rueda OM, Holmes KA, Theodorou V, and Robinson JLL, et al (2013).
Endogenous purification reveals GREB1 as a key estrogen receptor regulatory
factor. Cell Rep 3, 342–349. https://doi.org/10.1016/j.celrep.2013.01.010.
[33] Wu Y, Zhang Z, Cenciarini ME, Proietti CJ, Amasino M, Hong T, Yang M,
Liao Y, Chiang H-C, and Kaklamani VG, et al (2018). Tamoxifen Resistance in
Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis.
Cancer Res 78, 671–684. https://doi.org/10.1158/0008-5472.CAN-17-1327.
[34] Yu J, Chen L, Cui B,Widhopf GF, Shen Z,Wu R, Zhang L, Zhang S, Briggs SP,
and Kipps TJ (2016). Wnt5a induces ROR1/ROR2 heterooligomerization to
enhance leukemia chemotaxis and proliferation. J Clin Invest 126, 585–598.
https://doi.org/10.1172/JCI83535.
[35] Ford CE, Punnia-Moorthy G, Henry CE, Llamosas E, Nixdorf S, Olivier J,
Caduff R, Ward RL, and Heinzelmann-Schwarz V (2014). The non-canonical
Wnt ligand, Wnt5a, is upregulated and associated with epithelial to
mesenchymal transition in epithelial ovarian cancer. Gynecol Oncol 134,
338–345. https://doi.org/10.1016/j.ygyno.2014.06.004.
[36] Asem M, Buechler S, Wates R, Miller D, and Stack M (2016). Wnt5a Signaling
in Cancer. Cancer 8, 79. https://doi.org/10.3390/cancers8090079.
[37] Li P, Harris D, Liu Z, Liu J, Keating M, and Estrov Z (2010). Stat3 activates the
receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic
leukemia cells. PLoS One 5e11859. https://doi.org/10.1371/journal.
pone.0011859.
[38] Peng C, Zhang X, Yu H, Wu D, and Zheng J (2011). Wnt5a as a predictor in
poor clinical outcome of patients and a mediator in chemoresistance of ovarian
c a n c e r . I n t J G yn e c o l C an c e r 21 , 2 80–288 . h t t p s : / / do i .
org/10.1097/IGC.0b013e31820aaadb.
[39] Varma RR, Hector SM, Clark K, Greco WR, Hawthorn L, and Pendyala L
(2005). Gene expression profiling of a clonal isolate of oxaliplatin-resistant
ovarian carcinoma cell line A2780/C10. Oncol Rep 14, 925–932.
[40] Bordonaro M, Tewari S, Cicco CE, Atamna W, and Lazarova DL (2011). A switch
from canonical to noncanonicalWnt signalingmediates drug resistance in colon cancer
cells. PLoS One 6e27308. https://doi.org/10.1371/journal.pone.0027308.
[41] Katoh (2009). Transcriptional mechanisms of WNT5A based on NF-κB,
Hedgehog, TGFβ, and Notch signaling cascades. Int J Mol Med 23. https://doi.
org/10.3892/ijmm_00000190.
[42] Choi MY, Widhopf GF, Wu CCN, Cui B, Lao F, Sadarangani A, Cavagnaro J,
Prussak C, Carson DA, and Jamieson C, et al (2015). Pre-clinical Specificity and
Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1. Clin
Lymphoma Myeloma Leuk 15(Suppl), S167–S169. https://doi.org/10.1016/j.
clml.2015.02.010.
